Dupilumab, a monoclonal antibody which targets the IL-4R alpha subunit, has been approved for AD treatment for pediatric patients over 6 months of age.32 Dupilumab inhibits IL-4 and IL-13, which are key cytokines in the pathogenesis of AD. The gene discussed is IL13; the disease is Alzheimer disease.